EntryPoint Capital LLC Buys New Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

EntryPoint Capital LLC purchased a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,850 shares of the company’s stock, valued at approximately $229,000. EntryPoint Capital LLC owned about 0.08% of iTeos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of ITOS. SG Americas Securities LLC raised its stake in shares of iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares in the last quarter. Point72 DIFC Ltd acquired a new position in iTeos Therapeutics during the third quarter worth $31,000. Empowered Funds LLC raised its position in iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after acquiring an additional 3,305 shares in the last quarter. American Century Companies Inc. lifted its stake in iTeos Therapeutics by 7.5% in the fourth quarter. American Century Companies Inc. now owns 67,937 shares of the company’s stock valued at $522,000 after acquiring an additional 4,727 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock valued at $130,000 after acquiring an additional 4,843 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Down 5.7 %

Shares of NASDAQ:ITOS opened at $6.32 on Friday. iTeos Therapeutics, Inc. has a 12-month low of $6.30 and a 12-month high of $18.75. The business has a 50 day moving average of $7.27 and a 200-day moving average of $8.45. The stock has a market cap of $241.39 million, a PE ratio of -2.01 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.13. Equities research analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Thursday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. JPMorgan Chase & Co. decreased their target price on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price target on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.